
    
      Initially, patients will enter a short screening period, and those who continue to meet the
      inclusion and exclusion criteria will be randomized to receive either test or reference
      medicinal product in Period 1. In period 2 they will switch to the other formulation. During
      the whole treatment period four full-pharmacokinetics profiles will be established.
    
  